Substituent Q Contains Benzene Ring Patents (Class 564/161)
  • Patent number: 10696624
    Abstract: Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: June 30, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Xiang-Qun Xie, Abdulrahman Almehizia, Peng Yang
  • Patent number: 9950993
    Abstract: Disclosed herein are compounds of formula I: and salts thereof. Also disclosed are compositions comprising of compounds of formula I and methods using compounds of formula I.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: April 24, 2018
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Edmond J. LaVoie, Gifty A. Blankson, Ajit K. Parhi, Malvika Kaul, Daniel S. Pilch
  • Patent number: 9926261
    Abstract: Disclosed herein are compounds of formula I: and salts thereof. Also disclosed are compositions comprising of compounds of formula I and methods using compounds of formula I.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: March 27, 2018
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Edmond J. LaVoie, Ajit K. Parhi, Gifty A. Blankson, Malvika Kaul, Daniel S. Pilch
  • Patent number: 9201001
    Abstract: Dendrimer-hydrazides are coupled to polycyclic aromatic hydrocarbons for use in the visual detection of the presence of low levels of fluoride in a sample. The dendrimers can have a phenyl core, a first generation of aralkyl ethers, and an optional second generation of aralkyl ethers. The compounds form gels with solvents. In the presence of fluoride ion, the gels undergo color changes and/or gel to liquid phase change.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: December 1, 2015
    Assignee: Indian Institute of Technology Madras
    Inventors: Prasad Edamana, Rajamalli Pachaiyappan
  • Patent number: 9090537
    Abstract: The present invention relates to an improved process for the preparation of pure compound of Formula-II, which is an intermediate in the preparation of Aliskiren and further conversion of compound of Formula-II into Aliskiren or its pharmaceutically acceptable salts.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: July 28, 2015
    Assignee: Mylan Laboratories Limited
    Inventors: Shankar Rama, Seshadri Rao Manukonda, Srinivasa Rao Dasari, Ramesh Dandala, Lakshmana Rao Vadali
  • Publication number: 20150045367
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Application
    Filed: December 19, 2012
    Publication date: February 12, 2015
    Inventors: Erik Verner, Wei Chen, Sriram Balasubramanian
  • Patent number: 8937083
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes related thereto.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: January 20, 2015
    Assignee: DowAgroSciences, LLC
    Inventors: Noormohamed M. Niyaz, Negar Garizi, Yu Zhang, Tony K. Trullinger, Ricky Hunter, Ann M. Buysse, Asako Kubota, Paul Renee LePlae, Jr., Daniel Knueppel, Christian T. Lowe, Dan Pernich, David A. Demeter, Timothy C. Johnson
  • Patent number: 8921391
    Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: December 30, 2014
    Assignee: RaQualia Pharma Inc.
    Inventors: Yukinori Take, Shinichi Koizumi, Takako Okumura, Kazuhiko Nonomura
  • Patent number: 8853392
    Abstract: In one aspect, the invention relates to compounds, including phenylethynylbenzamide derivatives, cycloalkylethynylbenzamide derivatives, styrylbenzamide derivatives, 4-(3-phenyl-1,2,4-oxadiazol-5-yl)benzamide derivatives, 4-(pyridinylethynyl)benzamide derivatives, and N1-phenylterephthalamide derivatives, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: October 7, 2014
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Charles David Weaver, Alice L. Rodriguez, Colleen M. Niswender, Carrie K. Jones, Richard Williams
  • Publication number: 20140228405
    Abstract: The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like.
    Type: Application
    Filed: August 8, 2012
    Publication date: August 14, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Naoki Tomita, Shigeo Kajii, Douglas Robert Cary, Daisuke Tomita, Shinichi Imamura, Ken Tsuchida, Satoru Matsuda, Ryujiro Hara
  • Publication number: 20140213587
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
    Type: Application
    Filed: December 2, 2013
    Publication date: July 31, 2014
    Applicant: KINEX PHARMACEUTICALS, LLC
    Inventor: David G. Hangauer, Jr.
  • Publication number: 20140206537
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: March 25, 2014
    Publication date: July 24, 2014
    Applicant: DOW AGROSCIENCES LLC
    Inventors: James E. Hunter, William C. Lo, Gerald B. Watson, Akshay Patny, Gary D. Gustafson, Dan Pernich, William K. Brewster, Debra L. Camper, Beth Lorsbach, Michael R. Loso, Thomas C. Sparks, Hemant Joshi, Adiraj Mandaleswaran, Ramadevi Sanam, Rambabu Gundla, Pravin S. Iyer
  • Patent number: 8779015
    Abstract: Provided are a recycling method for industrially, simply and effectively recycling a phenolic body from a phenolic antioxidant which is masked by an organoaluminum compound and contained in an olefin polymer obtained by supplying the masked phenolic antioxidant upon polymerization; and an olefin polymer obtained by this method. In a method for recycling a phenolic antioxidant wherein a phenolic antioxidant which is masked by an organoaluminum compound and contained in an olefin polymer obtained by supplying the masked phenolic antioxidant upon polymerization is recycled to a phenolic body, a nitrogen gas comprising water and/or a proton donor at a volume ratio of 1.0×10?6 to 2.5×10?2 with respect to 1 volume of nitrogen is brought into contact with the olefin polymer.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: July 15, 2014
    Assignee: Adeka Corporation
    Inventors: Naoshi Kawamoto, Tsuyoshi Urushihara, Kohei Okamoto, Tetsuya Seguchi
  • Patent number: 8779003
    Abstract: Disclosed herein is a method for prolonging analgesic effect of a membrane permeable local anesthetic in a subject in need thereof. The method uses cinnamaldehyde as an adjuvant which, when administered prior to or simultaneously with the administration of a local anesthetic, prolongs the analgesic effect of the local anesthetic. Also disclosed herein is a method for providing analgesic effect in a subject in need thereof. The method uses cinnamaldehyde as an analgesic compound which, when administered alone to the subject in an analgesically effective amount, provides the analgesic effect.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: July 15, 2014
    Assignee: Mackay Memorial Hospital
    Inventor: Yu-Chun Hung
  • Patent number: 8772541
    Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: July 8, 2014
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Xiang-qun Xie, Peng Yang, Rentian Feng
  • Patent number: 8765815
    Abstract: Compounds that can be used as openers or blockers of voltage-dependent potassium channels, and which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing or enhancing cortical and/or peripheral neuron activity, compositions containing same and methods utilizing same are disclosed. Also disclosed are modulators of voltage-dependent potassium channels, which exhibit blocking of a TRPV1 channel, and hence are useful in the treatment of TRPV1-related conditions.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: July 1, 2014
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Bernard Attali, Asher Peretz
  • Patent number: 8765820
    Abstract: Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized by deregulation of gene transcription, cell differentiation and proliferation, e.g. tumors, viral infections, are herein described. These compounds belong to the structural formula (I) wherein A and R3 are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to compositions containing them and to therapeutic use thereof.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: July 1, 2014
    Assignees: Universita Degli Studi di Roma “La Sapienza”, Fondazione IEO, Universita Degli Studi di Pavia, Universita Degli Studi di Milano
    Inventors: Saverio Minucci, Antonello Mai, Andrea Mattevi
  • Patent number: 8759400
    Abstract: The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, this invention relates to compositions and methods for selectively enhancing fungal sensitivity to antifungal compounds.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: June 24, 2014
    Assignee: MethylGene Inc.
    Inventors: Nafsika Georgopapadakou, Wenqi Hu, Nadia Campeol, Jean Bedard, Robert Deziel, Alain Ajamian
  • Publication number: 20140171308
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: William C. Lo, James E. Hunter, Gerald B. Watson, Akshay Patny, Pravin S. Iyer, Joshodeep Boruwa
  • Publication number: 20140171314
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: William C. Lo, James E. Hunter, Gerald B. Watson, Akshay Patny, Pravin S. Iyer, Joshodeep Boruwa
  • Publication number: 20140171309
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: DOW AGROSCIENCES LLC
    Inventors: William C. Lo, James E. Hunter, Gerald B. Watson, Akshay Patny, Pravin S. Iyer, Joshodeep Boruwa
  • Publication number: 20140171312
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: William C. Lo, James E. Hunter, Gerald B. Watson, Akshay Patny, Pravin S. Iyer, Joshodeep Boruwa
  • Patent number: 8722156
    Abstract: An embodiment of the disclosure provides a liquid crystal compound having the following formula: wherein A1, A2, and A3 are independently hydrogen, halogen, cyano, thiocyanato, or —OCF3; R1 is hydrogen, halogen, C1-C12 alkyl, C1-C12 alkoxy, C1-C12 haloalkly, C2-C12 alkenyl, or C2-C12 alkynyl; R2 and R3 are independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkly, cyano, thiocyanato, or —OCF3; and Z is a single bond, —O—, —CH2O—, —C(O)O—, —OCO—, —C(O)NH—, or —CH?CH—. In another embodiment, a liquid crystal display including the liquid crystal compound is also provided.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 13, 2014
    Assignee: Industrial Technology Research Institute
    Inventors: Jian-Wen Lin, Chun-Ming Wu, Shih-Hsien Liu, Kung-Lung Cheng, Chih-Lung Chin
  • Patent number: 8716527
    Abstract: Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2- substituted-p-quinone derivatives as disclosed herein.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: May 6, 2014
    Assignee: Edison Pharmaceuticals, Inc.
    Inventors: Andrew W. Hinman, Kieron E. Wesson, Orion D. Jankowski, Paul Mollard, William D. Shrader, Christopher R. Cornell
  • Patent number: 8716337
    Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: May 6, 2014
    Assignee: Pisgah Laboratories, Inc.
    Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
  • Patent number: 8698117
    Abstract: The present invention relates to compounds represented by the following Formulas (I) and (II), Ring-A of Formulas I and II can be, for example, an aryl group, and Q? and Q?? can each be independently selected from groups, such as, halogen, —OH, —CN, amine groups, amide groups, carboxylic acid ester groups, carboxylic acid groups, alkenyl groups, alkynyl groups, carbonate groups, sulfide groups, and sulfonic acid ester groups. The present invention also relates to photochromic compositions and photochromic articles that include one or more photochromic compounds, such as represented by Formula II.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: April 15, 2014
    Assignee: Transitions Optical, Inc.
    Inventors: Meng He, Anil Kumar, Darrin R. Dabideen
  • Patent number: 8680150
    Abstract: The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: March 25, 2014
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Lin Zhi, Andrew R. Hudson, Cornelis A. Van Oeveren, Steven L. Roach, Jason C. Pickens, Yixing Shen, Catalina Cuervo, Lino J. Valdez, Jillian Basinger, Virgina H. Grant
  • Patent number: 8664274
    Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: March 4, 2014
    Assignee: Siga Technologies, Inc.
    Inventors: Dongcheng Dai, Tove Bolken, Dennis E. Hruby, Thomas R. Bailey
  • Publication number: 20140057953
    Abstract: The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 2 (l7beta-HSD2) inhibitors of formula (I), their production and use, notably for the treatment and prophylaxis of sex steroid deficient diseases like osteoporosis in men and women.
    Type: Application
    Filed: March 2, 2012
    Publication date: February 27, 2014
    Inventors: Rolf Hartmann, Sandrine Marchais-Oberwinkler, Kuiying Xu, Ruth Werth
  • Patent number: 8658697
    Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: February 25, 2014
    Assignee: Siga Technologies, Inc.
    Inventors: Dongcheng Dai, Tove Bolken, Dennis E. Hruby, Thomas R. Bailey
  • Publication number: 20140051580
    Abstract: The present invention relates to agrochemical compositions comprising certain benzamide compounds and to the use of those benzamide compounds as adjuvants, especially in formulations,in particular in agrochemical formulations and in environmentally friendly formulations. The invention further extends to certain novel benzamide compounds and a process to prepare such novel compounds.
    Type: Application
    Filed: November 29, 2011
    Publication date: February 20, 2014
    Applicant: SYNGENTA LIMITED
    Inventor: Ian Perry
  • Publication number: 20140031341
    Abstract: An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRPs), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology.
    Type: Application
    Filed: December 19, 2011
    Publication date: January 30, 2014
    Applicants: UNIVERSITAT MUNSTER, GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jerome Aubert, Martin Steinhoff
  • Publication number: 20140031395
    Abstract: The present invention relates to compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also inflammatory diseases.
    Type: Application
    Filed: February 2, 2012
    Publication date: January 30, 2014
    Applicant: Bionomics Limited
    Inventors: Andrew Harvey, Audrey Fluck, Bruno Giethlen, Dharam Paul, Laurent Schaeffer
  • Patent number: 8618169
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: December 31, 2013
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Bernard Attali, Asher Peretz
  • Patent number: 8580752
    Abstract: The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical isomers or their dihydro or tetrahydro derivatives and an anti-infective drug useful in potentiating the bioefficacy of antiinfective drug. The combination of the present invention is useful in the treatment of certain infections and disease at lower concentration of anti-infectives necessary to inhibit the growth of microbial strains and may also find applications in reducing the resistance in microorganisms.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: November 12, 2013
    Assignee: Council of Scientitic and Industrial Research
    Inventors: Surrinder Koul, Jawahir Lal Koul, Subhash Chandra Taneja, Pankaj Gupta, Inshad Ali Khan, Zahid Mehmood Mirza, Ashwani Kumar, Rakesh Kamal Johri, Monika Pandita, Anita Khosa, Ashok Kumar Tikoo, Subhash Chander Sharma, Vijeshwar Verma, Ghulam Nabi Qazi
  • Patent number: 8563615
    Abstract: The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: October 22, 2013
    Assignees: Massachusetts Institute of Technology, The Broad Institute, Inc., Massachusetts General Hospital
    Inventors: Li-Huei Tsai, Ji-Song Guan, Stephen J. Haggarty, Edward Holson, Florence Wagner, Johannes Graeff
  • Patent number: 8557872
    Abstract: This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present disclosure provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: October 15, 2013
    Assignee: Amorepacific Corporation
    Inventors: Song Seok Shin, Jin Kwan Kim, Sun-Young Kim, Ki-Wha Lee, Byoung Young Woo, Joo-Hyun Moh, Yeon Su Jeong, Kyung Min Lim, Jin Kyu Choi, Hyun-Ju Koh, Young-Ho Park
  • Patent number: 8552212
    Abstract: The invention relates to a series of novel chiral phosphorus ligands of formulae (Ia) and (Ib): wherein R, 1-rR>4 and X are as defined herein. The invention also relates to chiral metal complexes prepared with these chiral phosphorus ligands. The chiral metal complexes are useful as catalysts for carrying out asymmetric hydro genation.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: October 8, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bo Qu, Chris Hugh Senanayake, Wenjun Tang, Xudong Wei, Nathan K. Yee
  • Publication number: 20130235320
    Abstract: An embodiment of the disclosure provides a liquid crystal compound having the following formula: wherein A1, A2, and A3 are independently hydrogen, halogen, cyano, thiocyanato, or —OCF3; R1 is hydrogen, halogen, C1-C12 alkyl, C1-C12 alkoxy, C1-C12 haloalkly, C2-C12 alkenyl, or C2-C12 alkynyl; R2 and R3 are independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkly, cyano, thiocyanato, or —OCF3; and Z is a single bond, —O—, —CH2O—, —C(O)O—, —OCO—, —C(O)NH—, or —CH?CH—. In another embodiment, a liquid crystal display including the liquid crystal compound is also provided.
    Type: Application
    Filed: April 26, 2013
    Publication date: September 12, 2013
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jian-Wen LIN, Chun-Ming WU, Shih-Hsien LIU, Kung-Lung CHENG, Chih-Lung CHIN
  • Patent number: 8492593
    Abstract: Amido-fluorophosphite compounds and catalyst systems comprising at least one amido-fluorophosphite ligand compound in combination with a transition metal are described. Moreover, the use of amido-fluorophosphite containing catalysts for transition metal catalyzed processes, especially to the hydroformylation of various olefins to produce aldehydes are also described.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: July 23, 2013
    Assignee: Eastman Chemical Company
    Inventor: Thomas Allen Puckette
  • Patent number: 8481598
    Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: July 9, 2013
    Inventors: Rahul Surana, Murali Divi, Anil Chhettry
  • Patent number: 8481593
    Abstract: The invention relates to the use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions, specifically to the use of at least one compound derived from para-coumaric acid having a general formula (I) below: in which, especially, Z represents an oxygen or an —NH— group; X and Y are identical and each represent a CH or CH2 group, as an active principle with depigmenting, free-radical-scavenging and/or antiinflammatory activity. The invention also relates to the use of the above compounds for cosmetic care or for the preparation of a pharmaceutical composition, especially for depigmenting an area of skin, having antiradical and/or antiinflammatory activity.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: July 9, 2013
    Assignees: BASF Beauty Care Solutions S.A.S., Universite Joseph Fourier-Grenoble 1
    Inventors: Sabrina Okombi, Delphine Rival, Ahcene Boumendjel, Anne-Marie Mariotte, Eric Perrier
  • Patent number: 8476426
    Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: July 2, 2013
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Louis Peglion, Aimee Dessinges
  • Patent number: 8455550
    Abstract: The present invention concerns compounds of general formula (1), where in:—-a- is a single or double bond, Ar is an aromatic group, substituted or unsubstituted, R1 and R2 each independently or together are: a hydrogen atom or C1-C6 alkyl group, branched or unbranched, saturated or unsaturated, substituted or unsubstituted; the groups R1 and R2 may also form a heterocycle, R3 and R3? each independently or together are a hydrogen atom or C1-C6 alkyl group, X is an oxygen atom or a sulphur atom, and the addition salts of the compounds of general formula (1) with pharmaceutically acceptable mineral acids or organic acids.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: June 4, 2013
    Assignee: Pierre Fabre Medicament
    Inventors: Stéphane Cuisiat, Adrian Newman-Tancredi, Olivier Vitton, Bernard Vacher
  • Patent number: 8445708
    Abstract: The invention relates to a process for preparing chiral octenoic acid derivatives, which constitute important intermediates in the preparation of medicament active ingredients, and also to novel intermediates which are used in the process for preparing the octenoic acid derivatives mentioned.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: May 21, 2013
    Assignee: Reuter Chemischer Apparatebau KG
    Inventors: Milan Soukup, Karl Reuter, Florian Stolz, Viktor Meier, Jofzsef Balint, Mark Kantor
  • Publication number: 20130123505
    Abstract: A carboxamide can be produced in a high yield by a method for producing a carboxamide, for example, represented by formula (4): (wherein R1 and R3 are as defined below), the method comprising a step of allowing a carboxylic acid ester represented by formula (1): (wherein R1 represents an optionally substituented C1-C20 hydrocarbon group or an optionally substituented C3-C20 heterocyclic group, and R2 represents an optionally substituented C1-C20 hydrocarbon group), an amine represented by formula (2): R3—NH2 ??(2) (wherein R3 represents a hydrogen atom or an optionally substituented C1-C20 hydrocarbon group), and a formamide compound represented by formula (3): (wherein R3 is as defined above) to react in the presence of a metal alkoxide.
    Type: Application
    Filed: July 13, 2011
    Publication date: May 16, 2013
    Inventors: Junichi Tomokawa, Takahiro Kimura, Norihiko Hirata
  • Patent number: 8440711
    Abstract: The present invention relates to (R,S) 2-aryl-2-fluoropropanoic acids, their single enantiomers (R) and (S), their derivatives amides and acylsulfonamides and to pharmaceutical compositions containing them, which are used in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonucleated neutrophils (PMN leukocytes) at inflammation sites. The present invention provides compounds for use in the treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the treatment of damages caused by ischemia and reperfusion.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: May 14, 2013
    Assignee: Dompe Pha.r.ma S.p.A.
    Inventors: Marcello Allegretti, Andrea Aramini, Maria Candida Cesta
  • Publication number: 20130116227
    Abstract: Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R1 is a substitutable aminosulfonyl group, etc.; R2 is a hydrogen atom, etc.; R3 is a hydrogen atom, etc.; R4 is a hydrogen atom, a halogen atom, hydroxy group, a substitutable amino group, a substitutable C1-6 alkoxy group, a substitutable 4- to 7-membered cyclic amino group, etc.; R5a, R5b and R5c are each independently hydrogen atoms, etc.; R6 is a halogen atom, a cyano group, etc.; R7 and R8 are each independently a hydrogen atom, etc.; and m is an integer such as 0.
    Type: Application
    Filed: July 12, 2011
    Publication date: May 9, 2013
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Seiji Katayama, Seiji Hori, Futoshi Hasegawa, Kuniko Suzuki
  • Publication number: 20130100394
    Abstract: An embodiment of the invention provides a liquid crystal compound having the following formula: wherein A1, A2, and A3 are independently hydrogen, halogen, cyano, thiocyanato, or —OCF3; R1 is hydrogen, halogen, C1-C12 alkyl, C1-C12 alkoxy, C1-C12 haloalkly, C2-C12 alkenyl, or C2-C12 alkynyl; R2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkly, cyano, or —OCF3; and Z is —O—, —CH2O—, —C(O)O—, —OCO—, —C(O)NH—, —CH?CH—, or —C?C—. In another embodiment, a liquid crystal display including the liquid crystal compound is also provided.
    Type: Application
    Filed: December 29, 2011
    Publication date: April 25, 2013
    Inventors: Jian-Wen Lin, Chun-Ming Wu, Shih-Hsien Liu, Kung-Lung Cheng, Chih-Lung Chin
  • Patent number: 8410176
    Abstract: The present invention discloses processes for the preparation of 3-[(1R,2R)-3-(dimethyl-amino)-1-ethyl-2-methyl-propyl]phenol (Tapentadol), salts thereof and related compounds of formula (A), including stereoisomers and pharmaceutically acceptable salts thereof, and to certain intermediates used in such process.
    Type: Grant
    Filed: December 26, 2010
    Date of Patent: April 2, 2013
    Assignee: Mapi Pharma Ltd.
    Inventors: Ehud Marom, Michael Mizhiritskii